UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Upstaging of Fibroepithelial Lesions: A Single-Institution Experience

Annals of surgical oncology, 2022-04, Vol.29 (4), p.2193-2199

2022

Volltextzugriff (PDF)

ASO Visual Abstract: Upstaging of Fibroepithelial Lesions—A Single-Institution Experience

Annals of surgical oncology, 2022-04, Vol.29 (4), p.2201-2201

2022

Volltextzugriff (PDF)

Gene Expression Profiling of Fibroepithelial Lesions of the Breast

International journal of molecular sciences, 2023-05, Vol.24 (10), p.9041

2023

Volltextzugriff (PDF)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10647-10659

2023

Volltextzugriff (PDF)

High Expression of Trophoblast Cell Surface Antigen 2 in Triple-negative Breast Cancer Identifies a Novel Therapeutic Target

American journal of clinical pathology, 2019-09, Vol.152 (Supplement_1), p.S37-S37

2019

Volltextzugriff (PDF)

The Genetic Landscape of Fibroepithelial Lesions of the Breast

Advances in anatomic pathology, 2023-11, Vol.30 (6), p.415-420

2023

Volltextzugriff (PDF)

Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors

Annals of diagnostic pathology, 2024-02, Vol.68, p.152226-152226, Article 152226

2024

Volltextzugriff (PDF)

Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.585-585

2022

Volltextzugriff (PDF)

Gene expression comparison between primary triple‐negative breast cancer and paired axillary and sentinel lymph node metastasis

The breast journal, 2020-05, Vol.26 (5), p.904-910

2020

Volltextzugriff (PDF)

Abstract P4-07-32: Mammaprint and Blueprint are prognostic of outcome following neoadjuvant chemotherapy

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P4-P4-07-32

2022

Volltextzugriff (PDF)

Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.565-565

2019

Volltextzugriff (PDF)

Clinicopathologic Characteristics and Patient Outcomes of Phyllodes Tumors: A Single Institution Experience

The American surgeon, 2021-10, Vol.87 (10), p.1533-1538

2021

Volltextzugriff (PDF)

Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS634-TPS634

2023

Volltextzugriff (PDF)

Flat epithelial atypia on core needle biopsy does not always mandate excisional biopsy

The breast journal, 2020-04, Vol.26 (4), p.679-684

2020

Volltextzugriff (PDF)

Gene expression comparison between primary estrogen receptor‐positive and triple‐negative breast cancer with paired axillary lymph node metastasis

The breast journal, 2021-05, Vol.27 (5), p.432-440

2021

Volltextzugriff (PDF)

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS624-TPS624

2022

Volltextzugriff (PDF)

High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival

Annals of diagnostic pathology, 2019-06, Vol.40, p.30-39

2019

Volltextzugriff (PDF)

Abstract OT2-04-04: Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT2-04-04-OT2-04-04

2020

Volltextzugriff (PDF)

Comparison of multiple oncotype DX® from the same patient

The breast journal, 2021-11, Vol.27 (11), p.828-831

2021

Volltextzugriff (PDF)

Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO5-19-08-PO5-19-08

2024

Volltextzugriff (PDF)

FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort

Oncotarget, 2016-11, Vol.7 (46), p.75729-75738

2016

Volltextzugriff (PDF)

The clinicopathologic significance of FOXC1 in BRCA -mutant breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1556-1556

2014

Volltextzugriff (PDF)

Abstract OT3-25-01: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT3-25-01-OT3-25-01

2023

Volltextzugriff (PDF)

BRCA‐mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin‐like Growth Factor II mRNA‐binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14

The breast journal, 2015-11, Vol.21 (6), p.596-603

2015

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Upstaging of Fibroepithelial Lesions: A Single-Institution Experience

ASO Visual Abstract: Upstaging of Fibroepithelial Lesions—A Single-Institution Experience

Gene Expression Profiling of Fibroepithelial Lesions of the Breast

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

High Expression of Trophoblast Cell Surface Antigen 2 in Triple-negative Breast Cancer Identifies a Novel Therapeutic Target

The Genetic Landscape of Fibroepithelial Lesions of the Breast

Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors

Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy

Gene expression comparison between primary triple‐negative breast cancer and paired axillary and sentinel lymph node metastasis

Abstract P4-07-32: Mammaprint and Blueprint are prognostic of outcome following neoadjuvant chemotherapy

Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis

Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer

Clinicopathologic Characteristics and Patient Outcomes of Phyllodes Tumors: A Single Institution Experience

Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Flat epithelial atypia on core needle biopsy does not always mandate excisional biopsy

Gene expression comparison between primary estrogen receptor‐positive and triple‐negative breast cancer with paired axillary lymph node metastasis

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial

High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival

Abstract OT2-04-04: Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial

Comparison of multiple oncotype DX® from the same patient

Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial

FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort

The clinicopathologic significance of FOXC1 in BRCA -mutant breast cancer

Abstract OT3-25-01: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial

BRCA‐mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin‐like Growth Factor II mRNA‐binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14

Aktive Filter

Suchergebnisse filtern